George Institute for

CONOXIA is a medicinal gas (oxygen) formulation in cryogenic form, sponsored by The George Institute and currently in Phase 3 development for Interstitial Lung Disease (ILD). The program is investigating whether high-flow oxygen can enhance oxygenation during exercise and optimize the benefits of pulmonary rehabilitation in ILD patients who experience oxygen desaturation during physical effort. Assigned internal code IIBSP-OXI-2017-18, the program is actively enrolling patients under NCT 2024-519541-30-00. The mechanism of action and specific molecular target remain undisclosed. As a gas medicinal product, CONOXIA represents a therapeutic approach distinct from conventional small-molecule pharmaceuticals, though it is classified under the small-molecule modality category in this profile. Regulatory approval status and commercial projections have not yet been disclosed. The Phase 3 milestone represents a significant advancement in clinical validation for oxygen therapy optimization in a chronic respiratory disease population with substantial unmet medical need.

Interstitial Lung Disease encompasses a heterogeneous group of progressive pulmonary disorders characterized by inflammation and fibrosis, resulting in progressive dyspnea and exercise limitation. Patients with ILD frequently experience oxygen desaturation during physical activity, limiting functional capacity and quality of life. Current management relies on supplemental oxygen therapy and pulmonary rehabilitation, yet optimization of oxygen delivery during exercise remains an area of clinical uncertainty. The CONOXIA trial addresses a specific clinical question: whether high-flow oxygen administration can meaningfully enhance oxygenation kinetics during exercise in the context of structured pulmonary rehabilitation, potentially improving exercise tolerance and functional outcomes.

The ILD patient population represents a significant unmet medical need, as disease progression remains difficult to arrest and functional decline is common despite existing therapies. Pulmonary rehabilitation is recognized as a cornerstone of ILD management, but the role of optimized oxygen supplementation during rehabilitation sessions has not been definitively established. A positive Phase 3 outcome could reshape clinical practice guidelines for oxygen prescription during rehabilitation and potentially expand the therapeutic use of high-flow oxygen systems in this population. The competitive landscape for ILD therapeutics includes antifibrotic agents and immunomodulatory approaches, but oxygen optimization during rehabilitation represents a distinct therapeutic angle with potential for rapid clinical adoption if efficacy is demonstrated.

Drug Class: Medicinal gas (oxygen, cryogenic formulation)

Modality: Small molecule (gas)

Route of Administration: Inhalation (high-flow oxygen delivery)

Mechanism of Action: Not yet disclosed

Molecular Target: Not yet disclosed

Related Therapies: Supplemental oxygen therapy, pulmonary rehabilitation programs, antifibrotic agents (pirfenidone, nintedanib), immunomodulatory therapies for ILD

Formulation: Cryogenic gas medicinal product (compressed/liquefied oxygen)

First Approval: Not yet disclosed

Patent Status: Not yet disclosed

United States (FDA): Regulatory status not yet disclosed. CONOXIA is in Phase 3 development; no Investigational New Drug (IND) application status, breakthrough designation, or fast-track status has been reported.

European Medicines Agency (EMA): Status not yet disclosed.

Japan (PMDA): Status not yet disclosed.

China (NMPA): Status not yet disclosed.

Related Drug in Dataset: Estropipate (vaginal hormone replacement) is approved in the United States under multiple ANDA applications (ANDA040135, ANDA040296, ANDA040359, ANDA081213, ANDA081214, ANDA081215, ANDA081216, ANDA083220, ANDA084710, ANDA089567, ANDA089582) by sponsors including Barr, Duramed Pharma, Pfizer, Pharmacia and Upjohn, and others; however, this is unrelated to CONOXIA.

As a medicinal gas product, CONOXIA may be subject to specialized regulatory pathways for gases and inhalation products. Specific regulatory designations, priority review status, and anticipated filing timelines remain not yet disclosed.

Strategic Implications: The George Institute's sponsorship of CONOXIA reflects a strategic focus on optimizing existing therapeutic modalities (oxygen therapy) within the ILD management paradigm rather than developing novel molecular entities. This approach may offer a faster regulatory pathway and lower development cost compared to de novo drug discovery, while addressing a specific clinical question about oxygen optimization during rehabilitation.

Clinical Significance: The trial's research question—whether high-flow oxygen enhances oxygenation during exercise in ILD patients undergoing pulmonary rehabilitation—targets a gap in clinical evidence. If positive, results could inform guidelines for oxygen prescription intensity during rehabilitation sessions and potentially improve functional outcomes in a population with limited therapeutic options.

Competitive Implications: CONOXIA does not directly compete with antifibrotic agents (pirfenidone, nintedanib) or immunomodulatory therapies for ILD, but rather represents a complementary management strategy. A successful Phase 3 outcome could enhance the clinical utility of pulmonary rehabilitation programs by optimizing oxygen delivery, potentially increasing adoption of structured rehabilitation in ILD centers.

Expected Catalysts: Phase 3 data readout and publication of trial results; regulatory submissions to FDA, EMA, or other agencies; potential label expansion or clinical guideline updates based on efficacy findings; commercial partnerships for distribution of cryogenic oxygen delivery systems.

Development Risks: Regulatory classification and approval pathway for medicinal gases remain uncertain; competitive pressure from alternative oxygen delivery technologies; clinical adoption dependent on demonstrated superiority over standard oxygen therapy; reimbursement challenges for gas medicinal products in various healthcare systems.